Federated Hermes, Inc. Rubius Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $781,389 - $5.91 Million	-989,100 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$17.6 - $25.91 $2.8 Million - $4.12 Million	-159,155 Reduced 13.86%	989,100 $17.7 Million
Q2 2021 Aug 16, 2021	SELL	$22.26 - $28.43 $3.85 Million - $4.92 Million	-173,100 Reduced 13.1%	1,148,255 $28 Million
Q1 2021 May 13, 2021	BUY	$8.02 - $32.01 $5.79 Million - $23.1 Million	721,355 Added 120.23%	1,321,355 $35 Million
Q4 2020 Feb 12, 2021	SELL	$4.23 - $8.73 $15,333 - $31,646	-3,625 Reduced 0.6%	600,000 $4.55 Million
Q3 2020 Nov 12, 2020	SELL	$4.65 - $6.25 $465 - $625	-100 Reduced 0.02%	603,625 $3.02 Million
Q2 2020 Aug 13, 2020	BUY	$4.01 - $6.88 $14,937 - $25,628	3,725 Added 0.62%	603,725 $3.61 Million
Q1 2020 May 13, 2020	BUY	$3.74 - $9.84 $1.03 Million - $2.71 Million	275,000 Added 84.62%	600,000 $2.67 Million
Q2 2019 Aug 14, 2019	BUY	$13.5 - $19.94 $1.05 Million - $1.56 Million	78,070 Added 31.62%	325,000 $5.11 Million
Q4 2018 Feb 13, 2019	SELL	$13.83 - $22.97 $1.43 Million - $2.37 Million	-103,070 Reduced 29.45%	246,930 $3.97 Million
Q3 2018 Nov 13, 2018	BUY	$20.06 - $26.94 $7.02 Million - $9.43 Million	350,000 New	350,000 $8.4 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.